trial

D-serine Augmentation of Neuroplasticity

NCTId NCT03711500
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Completed
Enrollment 45 (actual)
Sponsored by New York State Psychiatric Institute, Washington Heights Community Service
Primary completion 2021-04-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Completed
Enrollment
45 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2019-03-13
Primary completion
2021-04-30
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
D-serine

Sponsors

New York State Psychiatric Institute, Washington Heights Community ServiceLead Sponsor
Nathan Kline Institute for Psychiatric ResearchCollaborator

Sites

2 total
New York, United StatesOrangeburg, United States

Linked catalysts

1
D-serine Augmentation of Neuroplasticity — primary completion2021-04-30

Facts & assertions

4 sourced
Enrollment
45
Phase
PHASE1,PHASE2
Primary Completion Date
2021-04-30
Status
COMPLETED
relationships
The graph out of here
drug
D-serine
drug
lead_sponsor
New York State Psychiatric Institute, Washington Heights Community Service
company
collaborator
Nathan Kline Institute for Psychiatric Research
company
indication
Schizophrenia
indication
Schizo Affective Disorder
indication
Schizophrenia
indication